Incidence of peripheral intravenous catheter failure among inpatients: variability between microbiological data and clinical signs and symptoms. by Blanco-Mavillard, I. et al.
              
City, University of London Institutional Repository
Citation: Blanco-Mavillard, I., Rodríguez-Calero, M. A., de Pedro-Gómez, J., Parra-
García, G., Fernández-Fernández, I. and Castro-Sanchez, E. ORCID: 0000-0002-3351-9496 
(2019). Incidence of peripheral intravenous catheter failure among inpatients: variability 
between microbiological data and clinical signs and symptoms.. Antimicrobial Resistance & 
Infection Control, 8, 124.. doi: 10.1186/s13756-019-0581-8 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/24290/
Link to published version: http://dx.doi.org/10.1186/s13756-019-0581-8
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
RESEARCH Open Access
Incidence of peripheral intravenous
catheter failure among inpatients:
variability between microbiological data
and clinical signs and symptoms
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Ismael Fernández-Fernández1 and Enrique Castro-Sánchez6
Abstract
Background: Peripheral intravenous catheters (PIVCs) are the most widely used invasive devices among inpatients.
Catheter-related bloodstream infections (CRBSI) are serious yet preventable events for patients. Although the
contribution of PIVCs towards these infections is gradually being recognised, its role in the Spanish setting is yet to
be determined. We aimed to estimate the rate and incidence of PIVC failure at Manacor hospital (Spain) as baseline
within a wider quality improvement initiative.
Methods: Tips from all PIVC removed during December 2017 and January 2018 in hospital wards were cultured
semiquantitatively. The study population included all PIVCs inserted in adult patients admitted to any of three
medical and one surgical wards, emergency department, critical care unit and operating rooms. Clinical,
microbiological and ward information was collected by clinical researchers for each PIVC from insertion to removal
on the study sites. CRBSI was defined per international guidelines (i.e., Centers for Disease Control and Prevention,
USA). Data was analysed descriptively.
Results: Seven hundred and eleven tips were cultured, with 41.8% (297/711) reported as PIVC failure. The PIVC
failure rate density-adjusted incidence for hospital length of stay (HLOS) was 226.2 PIVC failure/1000 HLOS. 5.8%
(41/711) tips yielded positive isolates, with most frequent microorganisms Staphylococcus spp (S. epidermidis 29/41,
70.7%, S. aureus 2/41, 4.9%, S. hominis 2/41, 4.9%), and Acinetobacter baumannii (1/41, 2.4%). One S. aureus isolate
was methicillin-resistant. 53.6% (22/41) positive cultures were obtained from patients with local signs and
symptoms compatible with catheter-related infection (CRI), 2.4% (1/41) were compatible with CRBSI type 2 and that
clinical signs improve within 48 h of catheter removal (density-adjusted incidence for hospital stays of 16.7 PIVC-
CRI/1000 hospital-stays and 0.76 PVC-BSI/1000 hospital-stays respectively) and no patients were diagnosed CRBSI
type 3 with a bacterial growth concordant in tip and blood cultures. Most cases responded favourably to catheter
removal and management.
Conclusions: Our findings show that almost 42% PIVCs resulted in unplanned removal, amplifying the importance
in terms of morbidity, mortality and patient safety. A high number of positive tip cultures without clinical signs and
symptoms was observed. We underpin the importance to remove unnecessary PIVCs for the prevention of CRBSI.
Keywords: Peripheral intravenous catheter, Catheter failure, Adverse events, Catheter-related bloodstream
infections, Vascular access device
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Background
Peripheral intravenous catheters (PIVCs) are the most
widely used invasive device in hospitals worldwide [1].
These devices can lead patients to experience multiple
complications during the insertion, maintenance and
management of intravenous therapy during a hospital
admission [1–3]. PIVCs are indicated for short-term use,
usually around a week. However, up to 69% of PIVCs
are prematurely removed due to PIVC failure, defined as
unplanned PIVC removal with mechanical complications
(phlebitis, occlusion, infiltration) or infection before the
completion of any scheduled intravenous therapy [4, 5].
Catheter-related bloodstream infections (CRBSI), which
include those associated with the use of central venous
catheters (CVCs) and PIVCs, are serious yet preventable
adverse events for patients, with a high cost in terms of
morbidity and mortality [6–8]. CRBSIs account for ~ 40%
of all bloodstream infections (BSI) [3]. Specifically, the in-
cidence of PIVC-BSI is 0.1% or 0.5 per 1000 catheter-days
[9]. CRBSIs can prolong HLOS and result in up to 25%
attributable mortality rate [10, 11]. Treating each episode
of PIVC-BSI costs approximately US$45000 in The excess
hospitalization costs associated to the treatment of each
episode of PIVC-BSI amount to ~US$45000 [4, 6]. Health
organizations have implemented strategies aimed at
preventing and reducing PIVC failure rates due to the
complications reported [12].
To date, there have been few systematic attempts to
measure PIVC failure and CRBSI in hospitals of the
Spanish National Health System. Therefore, the main
purpose of this study was to estimate the rate and in-
cidence of mechanical and infectious PIVC failure at
Hospital Manacor (Spain) as baseline to inform the
components of a wider quality improvement initiative
in PIVC care due to be implemented in our setting
[13]. The secondary objectives were to characterise
PIVC failure, describe pathogenic microorganisms
isolated from catheter tips, and explore factors associ-
ated with the reason for catheter removal and positive
culture of isolates.
Methods
Study design and participants
We conducted a prospective, observational study at
Hospital Manacor which serves a population of 150,000
inhabitants in the eastern sector of Mallorca in Spain.
The hospital has 240 beds for all clinical specialities ex-
cept cardiac, thoracic and neuro surgery. Routine clinical
practice in our setting to manage failed catheters does
not include recommendations to systematically culture
the tip of every PIVC removed. However, in order to de-
termine with accuracy the frequency of catheters failing
due to infectious reasons it would be necessary to carry
out such serial culturing. Therefore, during the study the
tips from all PIVC removed in hospital wards between
November 28, 2017 and January 12, 2018 were cultured
via the semiquantitative roll plate method, cutting 1.7 to
2.3 cm off the distal segment of PIVC with sterile scis-
sors by clinicians. All tips were sent immediately to the
laboratory where tips were rolled 3–4 times onto a blood
agar plate at 37 °C for 72 h for culture. The plates were
examined daily with bacterial colonies counted as soon
as growth was detected. Positive cultures were defined
as those with ≥15 colony forming units (CFU). Diagno-
ses of CRBSI type 2 and type 3 were confirmed if a posi-
tive PIVC tip culture was associated with a positive
peripheral blood culture for the same microorganism
immediately before or within 48 h after catheter removal
or a differential time to positivity of blood culture ≥2 h
and absence of other infectious focus explaining the
positive blood culture result [14]. The local microbiolo-
gist followed up each tip culture for 7 days, observing
clinical signs and other relevant cultures.
The convenience sample included all PIVCs inserted
in adult patients (18-years or older) admitted to any of
three medical and one surgical wards, emergency depart-
ment, and the critical care unit and operating rooms. In-
formation about clinical and microbiological variables
together with ward details were collected by the clinical
researchers for each PIVC from insertion to removal on
each study site. Clinical staff in all wards were notified
about the study via face-to-face meetings together with
an informative video to facilitate study adoption and im-
plementation. The study was approved by the research
ethic committee of Hospital Manacor and Balearic
Islands (IB3492/17PI).
PIVC care and maintenance
All PIVCs were inserted by nurses following current hos-
pital policy. The skin was prepared with 2% chlorhexidine
in 70% isopropyl alcohol. All PIVs were non-winged cathe-
ters, with a needle-free valve directly connected to 10 cm
of extension tubing ending in a three-way connector. A
transparent dressing with polyurethane borders was ap-
plied at the insertion site to secure the PIVC in situ. All
PIVCs were flushed with sterile 0.9% sodium chloride after
every use and not used a “scrup-the-hub” technique.
Standard caps on all needleless connectors were in place
to minimize accidental tubing disconnections. The current
policy did not include routine disinfection of PIVC caps as
a preventive measure.
Outcomes
The primary outcome of the study was all-cause PIVC
failure, defined previously as unplanned PIVC removal
before the completion of therapy. PIVC failure could re-
sult from the following adverse events associated with
their use: Catheter-related infection (CRI) or CRBSI type
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1 (positive culture in tips removed from patients with
local signs or symptoms compatible with catheter
inserted site infection, type 2 and type 3 (primary BSI
without and with laboratory confirmed local PIVC
infection respectively, with clinical signs improve within
48 h of catheter removal, defined as per Clinical Practice
Guideline of Centers for Disease Control and Preven-
tion, USA [15]), dislodgement (entire PIVC dislodged
from the patient’s body), extravasation (inadvertent leak-
age of a vesicant solution into surrounding tissue),
obstruction (complete PIVC occlusion, whereby neither
aspiration nor infusion are possible) and phlebitis (de-
fined by at least one or more of the following: persistent
pain referred to PIVC, erythema, swelling, palpable
thrombosis of the cannulated vein).
Secondary outcomes were subtypes of PIVC failure
(CRBSI, dislodgement, extravasation, obstruction and
phlebitis), PIVC/hospital length of stay (HLOS) per pa-
tient (total number PIVCs during HLOS per patient),
PIVC characteristics (insertion site, insertion side, cannula
size, insertion ward, dressing and removal setting),
indwelling time (time from insertion to removal), PIVC
bacterial infection (> 15 colony forming units, CFU), and
microorganisms isolated.
Statistical analysis
The statistical analysis included a description of the
sample (continuous data represented by means and
standard deviation, and categorical data represented by
frequency and percentage tables), and bivariate analysis
with parametric and non-parametric tests, depending on
the nature of the distributions (correlation, ANOVA,
chi-square). For the calculation of incidence density re-
ferring to total hospital stay we omitted the HLOS of
wards not including during the study period. Data were
analysed using SPSS IBM Statistics version 25.
Results
Clinical characteristics and outcomes of the sample
During the study period (46 days) we analysed 711
PIVCs from 504 patients, mainly from medical wards
(398, 79%). There were 236 (46.8%) female patients with
a mean age of 68.5 years (SD, 18.2 years). The median
PIVCs per HLOS for the sample was 1.5 PIVCs per pa-
tient (SD, 0.9). The incidence density for total hospital
admissions was 1313. Regarding total PIVC/HLOS, 504
patients had 1 PIVC (70.9%), 138 carried 2 PIVCs
(19.4%) and 69 carried 3 or more PIVCs (9.7%).
We cultured 711 PIVC tips, mostly from patients in
medical wards (585, 82.3%). 297 PIVCs (41.8%) were
defined as PIVC failure, resulting in a density-adjusted
incidence for HLOS of 226.2 PIVC failure/1000 HLOS. 71
PIVCs failures out of 126 PIVC insertions occurred on
surgical wards (56.3%), therefore the setting with a highest
rate of PIVCs failure. Regarding subtypes of PIVC failure,
extravasation and phlebitis accounted for 33.3% of all
reasons for removal, and 41/711 (5.8%) positive. 22/41
(53.6%, 16.7 PIVC-CRI/1000 hospital-stays) of those
positive cultures were obtained from patients with local
signs and symptoms compatible with CRI. Additionally, 1/
41 (2.4%, 0.76 PIVC-BSI/1000 hospital-stays) cultures was
compatible with CRBSI, with clinical signs improving
within 48 h of catheter removal. There were no patients
diagnosed with CRBSI with concordant bacterial growth
isolated in catheter tip and blood culture (Fig. 1). No
serious adverse events were documented during the study.
The isolated microorganisms were Staphylococcus spp
–S. epidermidis 29/41 (70.7%), S. aureus 1/41 (2.9%),
methicillin-resistant S. aureus (MRSA) 1/41 (2.9%), S.
hominis 2/41 (4.9%), S. haemolyticus 2/41 (4.9%), S.
capitis 1/41 (2.9%), S. simulans 1/41 (2.9%)–, Corynebac-
terium spp. 1/41 (2.9%), Candida albicans 1/41 (2.9%),
non-fermenting gram-negative bacillus 1/41 (2.9%) and
Acinetobacter baumannii 1/41 (2.4%).
There were statistically significant differences between
the removal settings regarding female gender (p = 0.020),
mean PIVC per HLOS (p = 0.030), total PIVC per HLOS
(p = 0.017), PIVC failure (p < 0.001) and subtypes of
PIVC failure (obstruction, phlebitis, dislodgement,
extravasation and suspected infection; p < 0.001). All
variables associated with clinical characteristics and
outcomes are described in Table 1.
Table 2 offers information about the reasons for cath-
eter failure. Overall, 297/711 (41.8%) PIVCs resulted in
catheter failure. Patients over 65 years (202/297; 68.0%)
presented high rate of PIVC unplanned removal and co-
morbidity was observed. In addition, they had 2 or more
comorbidities (451/711; 63.4%). 335/711 (47.1%) of
PIVCs were inserted into an area of non-flexion, such as
the forearm. The majority of PIVCs (465/711, 65.4%)
were intravenous cannula size 20G and all 711 PIVCs
were secured with transparent polyurethane dressing. A
high number of PIVCs (329/711, 46.3%) had an indwell-
ing time ranging 48–96 h before removal. PIVCs were
inserted primarily at the emergency department (333/
711, 46.8%) or at hospital wards (263/711, 37%). 55
(7.8%) PIVC insertion ward data was not registered due
to fragmentation of electronic records between emer-
gency and hospital wards. The variables related to age
group (p = 0.456), comorbidity (p = 0.686) location (p =
0.210), laterality (p = 0.472), intravenous cannula size
(p = 0.452), indwelling time (p = 0.599) and clinical area
of insertion (p = 0.230) were not statistically significant
in relation to PIVC failure. However, a statistically
significant association was observed between catheter
failure and setting of removal (p = < 0.001).
Table 3 describes factors associated with the reason
for PIVC removal related to positive tip cultures. 18/41
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(43.9%) positive tips were associated unnecessary PIVCs,
which came from patients discharged or intravenous
therapy completed and removed. 23/41 (56.1%) positive
tips related to PIVC failure (obstruction, phlebitis and
extravasation). A higher number of positive tips (16/41,
39.1%) identified as obstruction with insertion site in-
flammation and extravasation compared to phlebitis
rates were observed.
Discussion
In this study almost 42% PIVCs resulted in failure, a rate
comparable to previous studies reporting 28–55% [16–20].
Few studies have dealt however with PIVC failure following
up CRBSI with microbiological culture of catheter tips in
medical and surgical hospital settings. This approach
allowed us to estimate with accuracy and reliability the rate
and incidence of PIVC failure at Hospital Manacor, includ-
ing the variety of subtypes of PIVC failure, and pathogenic
microorganisms isolated on catheter tips. We observed
higher PIVC failure, phlebitis and obstruction rates in surgi-
cal wards, which may be explained by the administration of
intravenous therapy in surgical patients, usually a higher
volume of antibiotics and analgesia in a short period of time
[21–23]. However, the female gender was associated with a
higher PIVC failure rate in the surgical setting [22]. There-
fore, we cannot directly attribute the cause to the setting
alone omitting the gender variable.
PIVC insertion care, maintenance and management of
intravenous therapy are common care interventions.
Therefore, PIVC failure disrupts intravenous therapy
workflow requiring a new PIVC placement, a situation
with potential for multiple complications, pain and
distress for patients plus an important demand on health
system resources [21, 22, 24]. To match the vascular
access devices (VAD) to the therapy prescribed and reduce
the devices unnecessarily inserted nurses must take into
account patient characteristics and type and duration of
treatment. In our study, 39% of patients carried more than
two PIVCs during their admission. The inadequacy of the
device suggests a negative patient experience and poor-
quality care. The availability of an algorithm to optimally
select a VAD could contribute towards avoidance of PIVC
failure and the deterioration of vessel health. The PIVC
reinsertion impose a considerable consumption of clinical
Fig. 1 Flow chart. PIVC Failure
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resources and time. For example, and focusing just on
staff costs, if the average annual salary of a registered
nurse is currently US$73,550 (or ~US$35.30 per hour),
and estimating the time employed for each PIVC reinser-
tion as approximately ten minutes, then each PIVC failure
would result in ~US$13,336 per year. However, the major-
ity of costs are indirect and relate to therapy and increased
HLOS associated to CRBSIs [25, 26].
Our study reported a low occurrence of CRBSI (2.4%),
and no PIVC-attributable BSI. These results are encour-
aging, in comparison with previous studies which
obtained one CRBSI in 6538 PIVCs [27] and one episode
of CRBSI in 5907 PIVCs [28]. However, a significant
number of positive tip cultures were obtained at removal
following completed intravenous therapy or at patient
discharge. It is remarkable that we did not observe a
greater CRBSI rates after obtaining high colonization
rates. This may be due to the safety culture implemented
for the early removal of PIVCs when intravenous therapy
is completed, as well as cases of unnecessary insertions,
by the infection control team. Despite the low incidence
of CRBSI type 2 detected (1/711, 0.7 per 1000 HLOS) in
our study, the volume PIVCs used warrants continued
attention and skilled care for its potential in terms of
morbidity, mortality and patient safety [29–32].
Traditionally, PIVCs had been given limited relevance
within CRBSI prevention strategies, underestimating the
magnitude of the problem [33]. CRBSIs have been more
frequently associated with medium and long-term cen-
tral intravenous devices [34, 35]. Theoretically, catheter
indwelling time is one of the major risk factors for PIVC
failure [21]. However, a Cochrane review concluded that
routine removal of indwelling PIVC did not reduce the
risk of CRBSI [36]. and therefore eliminated the recom-
mendation of routine removal of catheters at 72-96 h,
leaving the decision to the clinical judgment of nurses
[28]. Catheter removal is recommended when clinical
manifestations of catheter failure are detected. However,
we do not always eliminate the cause of infection when
we detect general symptoms related to CRBSI, removing
PIVC immediately. We observed that there were no stat-
ically significant differences in indwelling time in our
analysis of characteristics of PIVC failure. Previous stud-
ies confirmed that it is the overall exposure of the PIVC
use that increases risk [28]. In our study, all PIVCs were
appropriately dressed with transparent bordered polyur-
ethane at the insertion site to anchor the catheter. When
PIVCs are not properly secured, micromotions may en-
courage migration of microorganisms along the catheter,
leading to CRBSI [21, 37]. The low incidence of CRBSI
(2.4%) and the absence of PIVC-attributable BSI in our
study, despite the presence of many PIVCs isolated with
pathogen microorganisms, do not support systematically
performing tip cultures of PIVCs for the prediction of
CRBSI. The therapeutic approach to local clinical signs
of PIVC failure, such as extravasations, insertion site in-
flammations and phlebitis, should be the removal of
PIVCs with the observation of the onset of systemic
symptoms. Furthermore, we recommend the premature
remove of unnecessary PIVC when intravenous therapy
had been completed, as such an effective therapeutic ap-
proach for prevention CRBSI.
Our study presents some limitations that must be
taken into account before interpreting the results. Firstly,
we conducted a two-month prospective observational
study in a single facility, being a study with a relatively
short period of time due to the budget to carry out serial
catheter tip cultures. Future research must consider to
the implementation of a multimodal intervention will
decrease the incidence of PIVC failure associated in
adult inpatients, analysing the fidelity to the recommen-
dations within clinical practice guidelines for insertion
and management of PIVCs.
Conclusions
Our findings indicate that almost half of the PIVCs
required unplanned removal. Although potentially fatal
adverse events such as CRBSIs have a low incidence in
our study, it is remarkable in terms of morbidity, mortal-
ity, patient safety and additional clinical workload,
mainly for nurses. From the point of view of quality of
care, we recommend that organizations emphasize in-
creasing the improvement initiatives within a wider total
quality process that includes adequacy of vascular access
device, optimal PIVC insertion care, maintenance and
management of intravenous therapy, and proactive pur-
suit of premature removal opportunities, underpinning
the importance of removing unnecessary PIVCs.
Table 3 Diagnosis of positive tip cultures relating the removal reasons
CRBSI
colonised type 1 type 2 type 3
Intravenous therapy completed, or patient discharged, n (%) 18 (43.9)
Obstruction with insertion site inflammation, n (%) 4 (9.8) 0 0
Phlebitis, n (%) 6 (14.6) 1 (2.4) 0
Extravasation, n (%) 12 (29.3) 0 0
Suspected infection, n (%) 0 0 0
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